N/A N=1,027 Improving CarE for Community Acquired Pneumonia 1
Pneumonia Childhood
Primary: Exclusive Guideline-Concordant Antibiotic Therapy, First 24 Hours — 255; 284; 174; 120 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=70 Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics
Asthma
Primary: Immunogenicity of Pneumococcal Vaccination — 0.05; 0.05 [µg/ml]
Phase 3 N=527 Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
Pneumonia
Primary: Treatment Failure at 48 Hours (Two Full Days After Enrollment) — 20; 21 participants
N/A N=66 Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine
Community Acquired Pneumonia
Primary: Use of Antibiotics in Each Group — 9; 21 participants — p=0.01
Phase 3 N=23,738 COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine
Infections, Streptococcal
Primary: Number of Subjects With a First Episode Reported of Bacterial Community Acquired Pneumoniae (B-CAP) — 240; 304 Subjects
Phase 2 N=248 A Study of a Vaccine for Pneumonia in Adults and Toddlers in Kenya
Pneumonia
Primary: Highest Grade of Reactogenicity Events in the Adult Cohort: Vaccination 1 — 11; 12; 22; 1 Participants
N/A N=3,641 Prevalence of Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Children of 12-18 Months in 6 Cities, China
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Nasopharyngeal Carriage of Streptococcus Pneumoniae — 12.5; 7.2; 16.6; 9.3 percentage of participants
N/A N=74 Antibiotic Efficacy in Pneumonitis Following Paraffin (Kerosene) Ingestion in Children
Kerosene Pneumonitis
Primary: Treatment Failure — 3; 2 participants — p=>0.50
N/A N=536 Improving CarE for Community Acquired Pneumonia 1 (ICE-CAP2)
Pneumonia Childhood
Primary: Inappropriate Disposition — 7; 6 Participants
N/A N=120 Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Community Acquired Pneumonia
Pneumonia
Primary: Use of Antibiotics in Each Group — 28; 52 participants
N/A N=188 Implementing a Combination of Clinical Parameters, Biomarkers and SoCs for the Etiology Diagnoses of Pneumonia in Pediatric Patients
Pneumonia
Primary: White Blood Cells and Absolute Neutrophil Count Cut-off Levels for Distinguishing of Viral and Bacterial/Mixed Pathogens — 12.2; 6.15 10^3 cells/microliter — p=0.0048
N/A N=8,790 Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage
Nasopharyngeal Carriage of S. Pneumoniae
Primary: Nasopharngeal Colonization With PCV13 S. Pneumoniae — 20; 31; 166; 137 Participants — p=<0.05
Phase 3 N=89 Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine
Invasive Pneumococcal Disease
Primary: Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per…
Phase 3 N=2,628 CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia
Pneumonia
Primary: Risk of Treatment Failure. — 267; 253 participants
N/A N=297 Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers
Pneumococcal Disease
Primary: Prevalence of Streptococcus Pneumoniae in Nasopharynx — 76; 43; 86; 46 Participants
N/A N=300 A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHINESE CHILDREN AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS
Immunogenicity, Vaccine
Primary: Geometric Mean Concentrations (GMCs) of Pneumococcal Immunoglobulin G (IgG) by Cohort — 1.55; 0.12; 0.42; 0.07 microgram per milliliter (µg/mL)
N/A N=9,707 Nasopharyngeal Streptococcus Pneumoniae Carriage
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Carriage of Streptococcus Pneumoniae in Nasopharynx — 12.6 Percentage of Participants
Phase 3 N=97 Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)
Pleural Empyema
Primary: Time to Hospital Discharge — 9.0; 9.1 days
Phase 4 N=385 Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children
Pneumonia
Primary: Desirability of Outcome Ranking (DOOR) — 97; 107; 47; 42 Participants — p=<0.001
Early Phase 1 N=5 Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia
Pneumonia · Pediatric Respiratory Diseases · Antibiotic Use
Primary: Total Pilot Trial Enrollment — 0; 1 Participants
Phase 4 N=125 Development of Childhood Anti-Influenza Immunity
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
Phase 3 N=300 Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A
Infections, Streptococcal
Primary: Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes for Subjects Receiving Synflorix Vaccine Co-administered With Tritanrix-HepB/Hib and Polio Sabin…
N/A N=186 Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10
Pneumococcal Infections
Primary: Persistence of Humoral Immunity Following PCV10 Vaccination — 0.32; 0.35 micrograms per ml
Phase 2 N=1,803 Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
Infections, Streptococcal
Primary: Time to Occurrence of Any Acute Otitis Media (AOM) Diagnosed and Verified Against American Academic of Pediatrics (AAP) Criteria — 0.425; 0.442 Episodes per person-year…
Phase 4 N=506 A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
Pneumococcal Infections
Primary: Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar — 6.90; 7.16; 7.53; 9.45 μg/mL
Phase 4 N=156 Vaccinating Children After Chemotherapy
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Protective Titres to PCV13 Serotypes Post-immunization With PCV13+PPV23 — 40; 22 Participants
Phase 3 N=433 Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age
Hepatitis A
Primary: Number of Seropositive Subjects for Anti-HAV Antibodies — 106; 94 Participants
Phase 3 N=41,181 Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease
Infections, Streptococcal · Streptococcus Pneumoniae
Primary: Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of…
Phase 3 N=839 Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
Pneumococcal Disease
Primary: Percentage of Participants Reporting Prompted Local Reactions Within 7 Days After Vaccination — 37.7; 39.1; 37.2; 15.1 Percentage of participants
N/A N=411 Evaluation of Moderate to Severe Influenza Outcomes in Children
Influenza · Otitis Media · Lower Resp Tract Infection
Primary: Hospitalization — 26; 2 Participants